Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
University of Innsbruck
Innsbruck, AustriaPublicaciones en colaboración con investigadores/as de University of Innsbruck (49)
2024
-
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
European Journal of Cancer, Vol. 202
-
Consensus on surgical technique for sentinel lymph node dissection in cervical cancer
International Journal of Gynecological Cancer, Vol. 34, Núm. 4, pp. 504-509
-
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266
-
Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis
Journal of Hepatology
-
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma
American Journal of Hematology
-
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284
2023
-
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
Cancers, Vol. 15, Núm. 13
-
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692
-
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
European Journal of Cancer, Vol. 188, pp. 131-139
-
Prognostic factors in patients with uterine sarcoma: The SARCUT study
International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 897-904
-
Social media ambassadors and collaboration with OncoAlert: A European Network of Young Gynae Oncologists study of comparative Twitter analysis of #ESGO2021 and #ESGO2022
International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 964-970
-
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Clinical Cancer Research, Vol. 29, Núm. 21, pp. 4419-4429
2022
-
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384
-
EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)
Future oncology (London, England), Vol. 18, Núm. 31, pp. 3481-3492
-
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
European Journal of Cancer, Vol. 174, pp. 221-231
2021
-
Author Correction: The utility of Next Generation Sequencing for molecular diagnostics in Rett syndrome (Scientific Reports, (2017), 7, 1, (12288), 10.1038/s41598-017-11620-3)
Scientific Reports
-
Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial
Journal of the National Cancer Institute, Vol. 113, Núm. 7, pp. 917-923
-
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
Virchows Archiv, Vol. 478, Núm. 2, pp. 153-190
-
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Radiotherapy and Oncology, Vol. 154, pp. 327-353
-
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
International Journal of Gynecological Cancer, Vol. 31, Núm. 1, pp. 12-39